Krystal Biotech, Inc.
Formerly Krystal Biotech, LLC
Krystal Biotech, Inc. is listed today as Krystal Biotech, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2017 | $11 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Krystal Biotech, Inc. chose not to state its revenue in its newest notice of a funding round (Aug 2017).
SEC Form D · Aug 2017
The industry group it chose in its notices: Biotechnology.
SEC Form D · Aug 2017
That is all the official record says: Krystal Biotech, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Krystal Biotech, Inc. are on record.
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Dino A. Rossi | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2017) | SEC Form 3 |
| Sun Pharma (Netherlands) B.V. | Other | not stated | not stated | Held Series A preferred stock, 10% owner (Form 3, 2017) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 16 investors.
Largest shareholders today
Institutions holding Krystal Biotech, Inc. shares, as of Sep 30, 2026.
- FMR LLC$1.5 B14.98%
- BlackRock, Inc.$1.2 B12.12%
- Avoro Capital Advisors LLC$961 M9.75%
- State Street Corp$472 M4.79%
- Vanguard Portfolio Management LLC$428 M4.34%
- Vanguard Capital Management LLC$398 M4.04%
- Soleus Capital Management, L.P.$379 M3.85%
- Geode Capital Management, LLC$270 M2.74%
- Capital World Investors$259 M2.63%
- Hood River Capital Management LLC$223 M2.27%
- Price T Rowe Associates Inc /MD/$195 M1.98%
- Redmile Group, LLC$175 M1.78%
- William Blair Investment Management, LLC$173 M1.76%
- Dimensional Fund Advisors LP$156 M1.59%
- Goldman Sachs Group Inc$143 M1.45%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Krish S. Krishnan | Executive officer | Aug 2017 |
| Dan M. Janney | Director | Aug 2017 |
| Dino M. Rossi | Director | Aug 2017 |
| Doug M. Norby | Director | Aug 2017 |
| Krish S. Krishnan | Director | Aug 2017 |
| Suma M. Krishnan | Director | Aug 2017 |
Went public since 2017. Its SEC number is that of a company listed on a stock exchange.